Dr. Swayampakula Ramakanth
Recent Articles
Biopharma Shares Multiple 2025 Catalysts 01/17/2025
Innate Pharma SA's (IPHA:NASDAQ; IPH:Paris) long-term corporate strategy led to it recieving a Buy rating from H.C. Wainwright & Co.
Boston Biotech Reports Promising Interim Data 08/07/2024
Interim efficacy data reported for Elevation Oncology Inc.'s (ELEV:NASDAQ) EO-3021 as a monotherapy is competitive and potentially could be superior as a combination therapy, according to an H.C. Wainwright & Co. research note.
Bionic Medical Co. Has Sufficient Funds to Operate Through 2024 03/05/2024
Ekso Bionics Holdings Inc.'s fourth quarter of 2023 financial results were in line with estimates, according to H.C. Wainwright & Co.
California-Based Pharma Co.'s Progress Offers Upside 01/02/2024
While H.C. Wainwright & Co. lowered their price target, they still see upside for this pharmaceutical company.
Due to permission requirements, not all quotes are shown.
